Retinoids are natural and synthetic compounds related to retinoic acid that act through interaction with two basic types of nuclear receptors: retinoic acid receptors (RARα, RARβ and RARγ) and retinoid X receptors (RXRα, RXRβ and RXRγ) as ligand-activated, DNA-binding, transacting, transcription-modulating proteins involved in a general molecular mechanism responsible for transcriptional responses in target genes. Function of retinoids in organisms affecting broad spectrum of various biochemical and molecular biology reactions is unimaginable without fully functional nuclear receptors -retinoid inducible transcription factors. Retinoic acids exert tumour-suppressive activity due to their antiproliferative and apoptosis-inducing effects. A number of novel retinoids and rexinoids acting through cognate nuclear receptors have been tested both in vitro and in vivo, using cell culture or animal models for breast cancer.
INTRODUCTION
Breast cancer is still the most common form of cancer death in women in Europe, with 129 900 deaths in the year 2004 (1) . Chemoprevention, which is defined as the prevention of cancer by pharmacological agents that inhibit or reverse the process of carcinogenesis, has thus increasingly become the focus of breast cancer prevention efforts (2) . A number of novel retinoid derivatives, which appear to be of promise based on preclinical and epidemiological data, are at present under investigation. Retinoids comprising vitamin A (retinol), their natural metabolites are involved in the complex arrangements of physiological and developmental responses in many tissues of higher vertebrates that include embryonic development, vision, reproduction, bone formation, haematopoiesis, metabolism, growth and differentiation of a variety of cell types, apoptosis and processes of carcinogenesis. Important carboxyl group containing natural derivatives of retinol include all-trans -, 9-cis -and 13-cis retinoic acids. In higher organisms, all-trans retinoic acid is considered to be the main biologically active form of vitamin A (3).
NUCLEAR RETINOID RECEPTORS
Discovery of the nuclear receptor superfamily that includes nuclear receptors for steroid and thyroid hormones, retinoids, dihydroxyvitamin D 3 and a number of "orphan" nuclear receptors for which ligands are still unknown, was a breakthrough in the field of understanding retinoid mediated mechanism of action in the cell. It is generally accepted that those nuclear receptors represent a superfamily of hormone or other biologically active ligand-inducible transcription factors. The molecules of nuclear retinoid receptors contain several specific domains from which the amino terminal A/B-domain of the nuclear receptor molecule contains a constitutive activation function (AF-1). The central C-domain is a cysteine-rich DNA-binding region consisting of two highly conserved zinc fingers, the D-domain represents a highly flexible structure, and it plays a role as a hinge of the receptor molecule. The carboxy-terminal E-domain is responsible for both retinoid binding and dimerization, and it contains inducible transactivation function (AF-2) (4, 5) (Fig. 1) . All-trans retinoic acid receptors (RARs) upon all-trans retinoic acid binding act as all-trans retinoic acid-inducible transcription factors by directly interacting as heterodimers with 9-cis retinoic acid receptor (retinoid X receptor, RXR) (6) . The RAR/RXR heterodimer interacts with specific DNA response elements of target genes and its effect on transcription is mediated also through recruitment of coregulators (corepressors and coactivators). Ligand occupancy of both receptors in RAR/RXR heterodimers synergistically increases transcriptional activity. Diversity of the retinoic acidinduced signalling pathway is associated with existence of at least three subtypes of RARs (RAR α, RAR β, RAR γ) and three subtypes of RXRs (RXR α, RXR β, RXR γ) with distinct amino-and carboxy-terminal domains. RAR/RXR heterodimers bind to specific DNA sequence -retinoic acid response elements (RAREs), characterized by direct repeats of two hexamers (A/G)GGTCA separated predominantly by five nucleotides (DR+5) or two nucleotides (DR+2) (7-9) (Fig. 2 ). In the absence of all-trans retinoic acid, the RAR/RXR heterodimer recruits nuclear receptor corepressor proteins, e.g. nuclear receptor corepressor (N-CoR) or silencing mediator of retinoid and thyroid hormone receptor (SMRT) (10). All-trans retinoic acid binding leads to the dissociation of corepressor proteins and enables association of coactivator proteins with liganded receptor complex yielding in chromatin decondensation and activation of gene transcription. The retinoids selective for specific binding to RXRs are called rexinoids (11) and RXRs play an crucial role in the nuclear receptor mediated transcription processes for their ability to heterodimerize with many other members of nuclear receptor superfamily, including RARs, thyroid hormone receptors, vitamin D 3 receptor, peroxisome proliferator-activated receptor γ (PPARγ), liver X receptor (LXR) and farnesoid X-activated receptor (FXR) (12, 13) . RXRs behave as promiscuous dimerization partners for a large number of nuclear receptors, and thus play an integrative and crucial role in nuclear receptor mediated pathways, suggesting that specific RXR ligands (rexinoids) might modulate transcription processes of target genes independently of RARs (14-16).
ROLE OF RETINOIDS AND THEIR COGNATE NUCLEAR RECEPTORS IN BREAST CANCER CHEMOPREVENTION
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CHEMOPREVENTION OF BREAST CANCER BY RETINOIDS
Breast cancer development is associated with deregulation of cell growth and cell death. It has been shown that retinoids are able to inhibit mammary gland cancer in animal models and human breast cancer. They are effective inhibitors of breast cancer cells at the early stages of tumour progression and their effectiveness diminishes as tumours become more aggressive (17, 18) . 1-methyl-1-nitrosourea (MNU) is a well characterized carcinogen that induces adenocarcinomas in rat mammary gland with high specificity. This model has proven to be of resemblance to human breast cancer and is therefore of great interest for mammary gland tumour studies (19) . Our data has shown that among the total number of lesions classified, the percentage of invasive tumours ranged from 35% to 44% in female Sprague-Dawley rats treated with MNU. No metastases were observed in other organs in MNU treated animals (20) (21) (22) .
Recently, we have shown that expression of RARα, RXRα, thyroid hormone receptor-α, both α-and β-forms of estrogen receptors, nuclear receptor coregulators (N-CoR, SRC-1, SMRT) and epidermal growth factor receptor (EGFR) in rat was significantly increased in postlactating mammary gland when compared to that of nonlactating mammary tissue. Postlactating mammary glands were found to express all RAR and RXR subtypes studied when compared to nonlactating mammary tissues that express exclusively RARα and RXRα subtypes. Enhanced expression of a number of nuclear hormone receptors, their coregulators in mammary tissue of postlactating rats in comparison with nonlactating animals identify a potential role for retinoid, thyroid and estrogen signalling pathways also after lactation period (23) . Also, a different pattern of expression of retinoid or rexinoid receptors was found in MNU-induced mammary carcinomas in both hypothyroid and hyperthyroid rats (24) . In general, retinoids regulate expression of several hundred genes through binding to nuclear transcription factors. Thus, substantial progress has been made in understanding of retinoid metabolism and function (25, 26) . 9-cis retinoic acid, a high affinity ligand for RXRs as well as LGD1069 (Targretin, Bexarotene), a synthetic RXR-selective ligand were shown to have efficacy superior to all-trans retinoic acid as a chemopreventive compound in the MNU-induced rat mammary gland carcinoma model. Moreover, Targretin was very well tolerated during chronic therapy with no classic signs of "retinoid-associated" toxicities.
In animal mammary gland carcinoma models, additional promising retinoids are retinyl acetate or N-(4-hydroxyphenyl)retinamide (Fenretinide) (27) (28) (29) . Also, it has been referred that a combination of ligands for peroxisome proliferator-activated receptor-γ (PPARγ) as troglitazone and ligands for RARs and/or RXRs may have a marked therapeutic role for breast cancer (30) . The lack of RARβ gene expression is a typical feature for human breast cancer and is considered to be one of the major factors responsible for retinoid resistance in those neoplasias. Determination of the expression of all the subtypes of RARs and RXRs in a number of hormone-dependent and hormone-independent breast cancer cells have shown similar expression of RARα, RARγ, RXRα and RXRβ. However, alltrans retinoic acid was found to be a strong inductor of the RARβ gene expression in several hormone-dependent breast cancer cell lines. Due to up-regulation of RARβ by all-trans retinoic acid or other retinoids, the expression of RARβ apparently plays a critical role in increasing retinoid sensitivity. These data indicate that the deficiency of the RARβ expression and a deficient responsiveness of retinoids via RARβ may account for the ineffective AGGTCA AGGTCA AGGTCA AGGTCA
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Fig. 2. Retinoic acid response elements (RAREs), characterized by direct repeats of two hexamers AGGTCA separated by either two nucleotides (DR+2) or fi ve nucleotides (DR+5).
treatment with retinoids in patients with advanced breast tumour (14, 31, 32) . The potency of retinoids to inhibit proliferation of breast cancer cells was seen when retinoids were administered either alone or in combination with antiestrogens. In animal models, the synergistic effects in inhibiting the initiation and promotion of mammary gland tumours induced by carcinogens were observed when retinoids were used in combination with ovariectomy or antiestrogens. Tamoxifen and fenretinide combination therapy has been proven to be an active treatment regimen in metastasis breast cancer patients, however, not in estrogen receptor negative metastasis breast cancer or in patients whose disease had progressed on tamoxifen (14, 32) . Retinoids do not require estrogen receptors for their action, they may affect neoplastic transformation in estrogen-negative cells, in contrast to tamoxifen, whose primary mechanism of action is through estrogen receptors (33) . As to RARβ2 expression, it seems to be decreased in intraepithelial neoplasias through hypermethylation, since retinoids have been proposed as attractive partners for demethylating agents (34, 35) . Retinoids acting predominantly through RARβ can promote apoptosis in breast cancer cells as well as in other types of neoplasias (36) . Relationship between retinoids, which can act as effective cancer chemopreventive agents or potential chemotherapeutic compounds against breast cancer, and the regulation of the processes such as differentiation and apoptosis is very complex and requires identification of new target genes that might be involved in those processes. Recently, we have studied the effect of 13-cis retinoic acid on the gene expression profile of tumour tissue in a MNU-induced mammary gland carcinoma rat model by the use of a commercial cDNA macro array (Atlas rat toxicology array 1.2, Clontech). The results have shown different expression of a number of genes encoding nuclear proteins and proteins involved in vitamin A metabolism in the retinoid treated MNU group versus mock treated MNU group (37) .
CONCLUSION
In spite of a number of important findings achieved recently by many prestigious laboratories, the precise mechanism(s) by which natural or synthetic retinoids or retinoid inhibit breast cancer cell growth has not been completely elucidated. The generation of novel reinoids and rexinoid with receptor subtype selectivity has opened new opportunities for cancer therapy and chemoprevention. These compounds should be restricted to particular malignancies thus increasing the therapeutic benefit. In spite of that progress, there is still an urgent call for novel synthetic retinoids and retinoid with greater retinoid receptor selectivity, reasonable chemopreventive or chemotherapeutic effects and reduced toxicity and side effects (14, 38, and 39) .
